July 16, 2023July 16, 2023 CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in India India patent registration opens door to commercial agreements in an enormous market with high economic potential for CureLab Oncology
March 3, 2023March 3, 2023 CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022Novermber 5, 2022 Biotech Internship Opportunity! FDA/USDA liaison CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities.
September 14, 2022September 14, 2022 CureLab Research Results With Cats Published in Animals Journal Results published by CureLab scientists with the University of Camerino support targeting mammary gland cancers in cats via p62 plasmid
